Compare EU & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | IMMP |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 426.9M |
| IPO Year | N/A | N/A |
| Metric | EU | IMMP |
|---|---|---|
| Price | $2.79 | $2.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 187.7K |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,142,000.00 | $3,306,742.00 |
| Revenue This Year | $17.41 | $292.48 |
| Revenue Next Year | $95.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $1.01 | $1.32 |
| 52 Week High | $4.19 | $3.53 |
| Indicator | EU | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 47.85 |
| Support Level | $2.60 | $2.56 |
| Resistance Level | $3.13 | $3.23 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 16.67 | 31.34 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.